Latest news with #Curaleaf
Reuters
16-07-2025
- Business
- Reuters
Breakingviews - Big Cannabis puts its growth hopes in dud buds
LONDON, July 14 (Reuters Breakingviews) - The weed sector is not as high as it used to be. A slow revenue grind and relentless regulatory hits have left Big Cannabis facing a chronic funk. Budding opportunities, like the flowering German market, may see some North American groups cough up for a deal to plant a foreign seed. Yet a mellow mood, and puffed-out stock valuations, are probably baked-in for the foreseeable future. Back in 2021, the much-hyped movement seemed to be sparking into life. Nearly 18 million Americans admitted to using the herb on a daily basis, overtaking the near-15 million daily drinkers, according to a survey published in the journal Addiction, opens new tab. New York, Virginia, Connecticut and New Mexico legalised recreational cannabis, as Alabama did for medical use. Hopes abounded that then-President Joe Biden might breathe life into federal reform, making it easier for companies to access financial services and manage inventory across state lines. The ambient buzz saw the combined value of Curaleaf ( opens new tab, Green Thumb Industries ( opens new tab, Tilray Brands (TLRY.O), opens new tab and Trulieve Cannabis ( opens new tab peak at $37 billion in February 2021. The same quartet, whose operations span everything from growing to packaging and selling weed and related products, at the time had an eye-watering average valuation multiple of 15 times forward sales, according to Breakingviews calculations based on LSEG Datastream figures. The dreams behind those numbers, however, have gone up in smoke. That much was evident at an industry gathering at the Barbican Centre in London last month, where top investors, CEOs and bankers bluntly hashed out the sector's biggest risks and opportunities. Attendees of Cannabis Europa, opens new tab, some bleary-eyed after wading through plumes of smoke, heard that right-leaning governments worldwide are blocking the opening up of new recreational markets. Sticky corporate debt burdens and low valuation multiples, meanwhile, have made expansion tricky. It's reflected in the stock market. Curaleaf, Green Thumb, Tilray and Trulieve are now collectively worth just $4 billion, LSEG data shows, with an average forward revenue multiple of just over 1. On aggregate, they'll make a loss this year and next, based on analysts' forecasts gathered by Visible Alpha. One long-term problem is that legalisation in the United States and Canada sparked a rush of supply, leading to a glut of marijuana and therefore much lower prices amid cutthroat competition. In New York, the number of registered dispensaries has exploded since legalisation in 2021 to 300 now, according to the Office of Cannabis Management. Average U.S. retail prices have declined by 32% over the same period, according to Cannabis Benchmarks, opens new tab. Companies are also facing the stark reality of a total addressable market that looks stagnant at best. As U.S. state laws criminalising the herb fell like dominoes, investors once thought other countries would eventually succumb too. That now looks like a pipe dream. Not a single U.S. state has legalised recreational cannabis this year or in 2024. President Donald Trump's government seems unlikely to do much. The Drug Enforcement Administration last year indicated that it might downgrade weed from the schedule one category under the Controlled Substances Act to schedule three, which could ease some federal restrictions and make more expenses tax-deductible. The process now seems stalled, however. In other markets, progress is being stubbed out. Last month, Thailand moved to ban recreational use amid concerns about addiction in younger users, having taken the drug off its narcotics list only three years earlier. Amid the haze, boosters are finding solace in an unlikely place. Germany last year decriminalised cannabis possession and small-scale production, while stopping short of allowing wholesale cultivation. Bankers and investors at the London conference giddily talked up the prospects of inbound Teutonic M&A, as companies in the U.S. and Canada look to take advantage of potential growth in Europe's biggest economy. Privately owned Demecan or Cannamedical could be prime targets. The legal German cannabis market could grow by 14% each year until 2030, according to a report from Research and Markets, opens new tab. But it's starting from a low base. Last year, the market was worth just $37 million. And there are other obstacles. Planned licences for pot shops and pharmacies, for example, have failed to materialise amid concerns from European leaders about a surge in illegal exports. It's all a far cry from the multibillion-dollar global dreams of a few years ago. But there's not much else to get excited about. Amid a drought of optimism, even the most unpromising of buds can seem like salvation. Follow Aimee Donnellan on LinkedIn, opens new tab.
Yahoo
08-07-2025
- Business
- Yahoo
Why Curaleaf Stock Is Smoking Hot Today
Curaleaf is buying out its minority partner in Europe. The former strategic investor in Curaleaf's European subsidiary is remaining invested in Curaleaf itself. Curaleaf generates substantial free cash flow and is growing nicely. 10 stocks we like better than Curaleaf › Curaleaf Holdings (OTC: CURLF), one of only a handful of publicly traded cannabis stocks that are headquartered in the U.S., jumped 4.8% through 11:30 a.m. ET Tuesday after announcing it has consolidated its stake in its European holding company, Curaleaf International Holdings Limited (CIHL). Curaleaf now owns 100% of the subsidiary. Since its initial foray into Europe in 2021, Curaleaf advises, an unnamed "single strategic institutional investor" has owned part of the equity in CIHL. Now Curaleaf owns it all, and takes all the risk that the business may perform poorly -- and will reap all the rewards if CIHL performs well. Curaleaf seems to think the latter option is more likely, as does its former institutional investor -- which has "elected to receive the purchase entirely in Curaleaf Subordinate Voting Shares." This means the investor eschewed the safety of getting paid in cash, and instead is keeping its cart firmly hitched to the horse that is the Curaleaf parent company. Or as Curaleaf put it: "The request of the strategic investor to settle the transaction for Company shares underscores the investor's long-term support and confidence in the future of Curaleaf." Practically speaking, it's as if the strategic investor took payment from Curaleaf for its stake in the subsidiary, and then immediately used that payment to buy shares in Curaleaf itself. But is Curaleaf stock really a good buy? I think it is. Curaleaf is the only marijuana stock I know of that generates positive free cash flow, nearly $63 million over the last year. That gives the stock a price-to-free cash flow ratio of almost exactly 10. So long as Curaleaf can maintain even a low-double-digit growth rate going forward, that should be cheap enough to buy. Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Is Smoking Hot Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
08-07-2025
- Business
- Globe and Mail
Curaleaf to Report Second Quarter 2025 Financial and Operational Results
STAMFORD, Conn. , July 8, 2025 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the second quarter ended June 30, 2025 after market close on August 6, 2025 . Management will host a conference call and audio webcast that afternoon at 5:00 p.m. ET consisting of prepared remarks followed by a question-and-answer session related to the Company's operational and financial highlights. For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 13, 2025 , and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 ( Canada ) or +1-412-317-0088 (International) and entering replay pin number: 1472267 About Curaleaf Holdings Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit Investor Relations Website: Investor Contact: Curaleaf Holdings, Inc. Camilo Lyon , Chief Investment Officer IR@ Media Contact: Curaleaf Holdings, Inc. Jordon Rahmil, VP Corporate Communications media@ View original content to download multimedia: SOURCE Curaleaf Holdings, Inc.
Yahoo
08-07-2025
- Business
- Yahoo
Curaleaf to Report Second Quarter 2025 Financial and Operational Results
STAMFORD, Conn., July 8, 2025 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the second quarter ended June 30, 2025 after market close on August 6, 2025. Management will host a conference call and audio webcast that afternoon at 5:00 p.m. ET consisting of prepared remarks followed by a question-and-answer session related to the Company's operational and financial highlights. Event:Curaleaf Second Quarter 2025 Financial Earnings Conference Call Date:Wednesday, August 6, 2025 Time:5:00 p.m. ET Live Call:+1-844-512-2926 (U.S.), +1-416-639-5883 (Canada) or +1-412-317-6300 (International) Passcode:3090114 Webcast: interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 13, 2025, and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 (Canada) or +1-412-317-0088 (International) and entering replay pin number: 1472267 About Curaleaf Holdings Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit Curaleaf IR Twitter Account: Investor Relations Website: Investor Contact: Curaleaf Holdings, Lyon, Chief Investment Officer IR@ Media Contact: Curaleaf Holdings, Rahmil, VP Corporate Communicationsmedia@ View original content to download multimedia: SOURCE Curaleaf Holdings, Inc. View original content to download multimedia:
Cision Canada
08-07-2025
- Business
- Cision Canada
Curaleaf to Report Second Quarter 2025 Financial and Operational Results
STAMFORD, Conn., July 8, 2025 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the second quarter ended June 30, 2025 after market close on August 6, 2025. Management will host a conference call and audio webcast that afternoon at 5:00 p.m. ET consisting of prepared remarks followed by a question-and-answer session related to the Company's operational and financial highlights. For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 13, 2025, and can be accessed by dialing +1-877-344-7529 (U.S.), +1-855-669-9658 (Canada) or +1-412-317-0088 (International) and entering replay pin number: 1472267 About Curaleaf Holdings Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit Investor Relations Website: Investor Contact: Curaleaf Holdings, Inc. Camilo Lyon, Chief Investment Officer [email protected] Media Contact: Curaleaf Holdings, Inc. Jordon Rahmil, VP Corporate Communications [email protected] SOURCE Curaleaf Holdings, Inc.
